Takeda Pharmaceutical (TKPHF) Change in Account Payables (2018 - 2026)

Takeda Pharmaceutical's Change in Account Payables history runs 9 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 54.81% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at -$27.8 million (up 32.72% YoY), while the FY2026 annual figure was -$20.9 million, up 55.22% from the prior year.
• Change in Account Payables was $30.6 million for Q1 2026 at Takeda Pharmaceutical, up from $21.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $1.1 billion in Q1 2022 to a low of -$751.0 million in Q2 2022.
• Historically, Change in Account Payables has averaged $17.3 million across 5 years, with a median of $2.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Change in Account Payables tumbled 302.34% in 2022, then jumped 4352.61% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$54.6 million in 2022, then jumped by 970.94% to $475.4 million in 2023, then tumbled by 72.84% to $129.1 million in 2024, then tumbled by 83.43% to $21.4 million in 2025, then jumped by 43.01% to $30.6 million in 2026.
• The last three Change in Account Payables figures came in at $30.6 million (Q1 2026), $21.4 million (Q4 2025), and $112.2 million (Q3 2025), per Business Quant data.